A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib
Pediatric Neurosurgery · 2024 · 59 (1) · 27-34
DOI: 10.1159/000535842 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Neurosurgery, online erschienen am 18.12.2023. Verfasst von Emery Buckner-Wolfson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Glioma. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Infant-type hemispheric glioma (IHG) is a rare form of cancer that affects newborns and infants. It is classified as a pediatric-type high-grade glioma and typically harbors receptor tyrosine kinase (RTK) gene fusions. Here, we present the finding of a novel gene fusion IHG treated with a targeted therapy that has yet to be implemented for any other IHG case to date. Case Presentation: We report the case of a 12-month-old boy with IHG who presented with obstructive hydrocephalus due to a large mass in the right frontal lobe. The patient initially underwent mass resection, but subsequent imaging showed rapid interval progression of the residual tumor. Comprehensive molecular analysis of the tumor tissue revealed a novel GAB1-ABL2 gene fusion, and the patient was started on dasatinib, an ABL kinase inhibitor. Shortly after initiation of dasatinib treatment, there was a significant reduction in tumor size and enhancement, followed by stabilization of disease.
Discussion
The patient’s robust response to treatment suggests that dasatinib is an effective targeted therapy for IHG harboring a GAB1-ABL2 gene fusion. This finding may inform future investigations into the disease processes of IHG and help guide the diagnosis and treatment of IHG in the absence of previously identified gene fusions, improving clinical management of this vulnerable patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Pediatric Neurology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Pathology, Montefiore Medical Center, Bronx, New York, USA.
- Department of Pediatric Hematology, Oncology, and Cellular Therapy, Albert Einstein College of Medicine, Bronx, New York, USA.
Zitieren
APA
Buckner-Wolfson, E., Jung, G., Kim, T., Fatemi, R., Liriano, G., Dalvi, N., Behbahani, M., Chin, S., Martin, A., & Kobets, A. (2024). A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib. Pediatric Neurosurgery, 59(1), 27-34. https://doi.org/10.1159/000535842
Vancouver
Buckner-Wolfson E, Jung G, Kim T, Fatemi R, Liriano G, Dalvi N, et al. A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib. Pediatric Neurosurgery. 2024;59(1):27-34. doi:10.1159/000535842
BibTeX
@article{BucknerWolfson2024,
author = {Buckner-Wolfson, Emery and Jung, Geena and Kim, Timothy and Fatemi, Ryan and Liriano, Genesis and Dalvi, Nagma and Behbahani, Mandana and Chin, Steven and Martin, Allison and Kobets, Andrew},
title = {A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib},
journal = {Pediatric Neurosurgery},
year = {2024},
volume = {59},
number = {1},
pages = {27--34},
doi = {10.1159/000535842}
}
EUVIMED